Page last updated: 2024-08-17

carbostyril and Agnogenic Myeloid Metaplasia

carbostyril has been researched along with Agnogenic Myeloid Metaplasia in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barosi, G; Rosti, V	1
Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D	1
Gray, LA; Kaufmann, SH; Mesa, RA; Reeder, T; Schroeder, G; Tefferi, A	1
Odenike, O; Tefferi, A	1
Camoriano, JK; Erlichman, C; Finke, C; Geyer, SM; Kaufmann, SH; Lasho, T; Li, CY; Mesa, RA; Pardanani, A; Rivera, CE; Tefferi, A; Wright, J; Wu, W	1

Reviews

2 review(s) available for carbostyril and Agnogenic Myeloid Metaplasia

Article	Year
Novel strategies for patients with chronic myeloproliferative disorders. Current opinion in hematology, 2009, Volume: 16, Issue:2 Topics: Chronic Disease; Humans; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Mutation; Myeloproliferative Disorders; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Quinolones; Recombinant Proteins; Thalidomide	2009
Conventional and new treatment options for myelofibrosis with myeloid metaplasia. Seminars in oncology, 2005, Volume: 32, Issue:4 Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins	2005

Trials

2 trial(s) available for carbostyril and Agnogenic Myeloid Metaplasia

Article	Year
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, Mar-01, Volume: 101, Issue:5 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia, 2007, Volume: 21, Issue:9 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome	2007

Article

Year

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

Blood, 2003, Mar-01, Volume: 101, Issue:5

Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003

A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.

Leukemia, 2007, Volume: 21, Issue:9

Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Bone Marrow; Female; Humans; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinolones; Thrombocythemia, Essential; Treatment Outcome

2007

Other Studies

1 other study(ies) available for carbostyril and Agnogenic Myeloid Metaplasia

Article	Year
In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia, 2003, Volume: 17, Issue:5 Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Survival; Cells, Cultured; Chromones; Colony-Forming Units Assay; Enzyme Inhibitors; Erythrocyte Count; Farnesyltranstransferase; Female; Flavonoids; GPI-Linked Proteins; Hematopoietic Stem Cells; Humans; Male; Membrane Glycoproteins; Mesothelin; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Proteins; Quinolones; Thrombocythemia, Essential	2003

Article

Year

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.

Leukemia, 2003, Volume: 17, Issue:5

Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Survival; Cells, Cultured; Chromones; Colony-Forming Units Assay; Enzyme Inhibitors; Erythrocyte Count; Farnesyltranstransferase; Female; Flavonoids; GPI-Linked Proteins; Hematopoietic Stem Cells; Humans; Male; Membrane Glycoproteins; Mesothelin; Middle Aged; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Proteins; Quinolones; Thrombocythemia, Essential

2003